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ABSTRACT 
Mycothiol (MSH) is unique to mycobacteria as the major low molecular weight cellular thiol responsible 
for protection of bacteria against oxidative stress. The design of drugs and inhibitors against enzymes of the 
mycothiol pathway was based on the premise that mycothiol is unique to mycobacteria, and is thus 
important for its survival. A total of 80 inhibitors designed against enzymes of the mycothiol pathway were 
screened for inhibition of growth on in vitro growing M. tuberculosis using the BACTEC 460
TM
 assay. The 
most active compounds were further tested for inhibitory potential of M. tuberculosis within macrophages. 
Initial screening in the macrophage system was done using the human-like THP1 cell line and then mouse 
bone marrow-derived macrophages. In this investigation we established that phenothiazine can be exploited 
as an inhibitor of enzymes of the mycothiol pathway. Although tunicamycin significantly inhibited the 
growth of M. tuberculosis both in vitro and ex vivo; it was found to be cytotoxic to host macrophages. To 
this end we provide proof-of-concept that compounds which can inhibit the expression of mycothiol 
enzymes have potential as anti-tubercular drugs. 
 
The response of M. tuberculosis to stress conditions was assessed via LC-MS in which maximal levels of 
mycothiol were produced during the early time points of exposure to isoniazid. We used mycothiol-
deficient (mshA) M. tuberculosis to investigate the role of mycothiol for survival as well as the resultant 
phenotype when such mutants are exposed to stress conditions. The mshA deletion mutants in M. 
tuberculosis were resistant to INH at concentrations which inhibited growth in the wild-type strains. We 
postulated that katG and inhA, the genes involved in INH metabolism, required mycothiol for their 
activation.  
 
Morphological alterations of M. tuberculosis within macrophages were assessed using electron microscopy 
approaches. In this way we attempted to follow the fate of M. tuberculosis within the phagosomes, and how 
mycobacteria is processed in phagosomes in terms of replication, survival and degradation. The 
establishment of a successful infection by M. tuberculosis depends on the initial encounter with host 
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macrophages, which represent the first line of cellular defense against microbial invasion. At the interface 
between mycobacteria and macrophages, the complex outermost layer of the mycobacterial cell wall 
probably plays a role in facilitating host cell entry. Under normal conditions (i.e. ingestion of non 
pathogenic microorganisms), newly formed phagosomes intermingle contents and membrane with the 
successive compartments of the endocytic pathway (early endosomes, late endosomes, lysosomes) through 
a complex series of fusion and fission. As they are processed into phagolysosomes, they undergo gradual 
modifications by specific addition and removal of membrane constituents. In addition, they become 
acidified due to the vacuolar proton pump ATPase located in the membrane and acquire toxic constituents, 
including hydrolases that will ultimately destroy bacteria.  
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OPSOMMING 
Mycothiol (MSH) is uniek aan mycobacteria as die belangrikste lae molekulêre gewig sellulêre thiol 
verantwoordelik vir die beskerming van bakterieë teen oksidatiewe stres. Die ontwerp van dwelms en 
inhibeerders teen ensieme van die mycothiol pad is gebaseer op die veronderstelling dat mycothiol uniek is 
aan mycobacteria, en is dus belangrik vir sy oorlewing. „n Totaal van 80 inhibeerders ontwerp teen ensieme 
van die mycothiol pad is gekeur vir die inhibisie van groei op in vitro groeiende M. tuberculosis met behulp 
van die BACTEC 460
TM
 toets. Die mees aktiewe verbindings is verder getoets vir inhiberende potensiaal 
van M. tuberculosis binne makrofage. Aanvanklike sifting in die makrofage stelsel is gedoen met behulp 
van die mens-soos THP1 sel lyn dan makrofage afkomstig van muis beenmurg. In hierdie ondersoek het 
ons vasgestel dat fenotiasien kan gebruik word as „n inhibitor van ensieme van die mycothiol pad. 
Alhoewel tunicamycin aansienlik die groei van M. tuberculosis beide in vitro en ex vivo inhibeer, was dit 
gevind word sitotoksies is vir makrofage. Om hierdie rede het ons bewys-van-konsep wat verbindings dat 
die uitdrukking van mycothiol ensieme inhibeer, die potensiaal het as anti-tuberkulose dwelms. 
 
Die reaksie van M. tuberkulose op stress is geëvalueer deur LC-MS waarin maksimum vlakke van 
mycothiol gedurende die vroeë tyd punte van blootstelling aan isoniasied geproduseer is. Ons gebruik 
mycothiol-deficient (mshA) M. tuberculosis om die rol van mycothiol vir oorlewing sowel as die gevolglike 
fenotipe te ondersoek wanneer sodanige mutanten blootgestel word aan stres kondisies. Die mshA-
weglating mutanten van M. tuberculosis was bestand teen INH konsentrasies wat groei geïnhibeer in die 
wilde-tipe-stamme. Ons veronderstel dat katG en inhA, die gene wat betrokke is in INH metabolisme, 
mycothiol vereis vir hulle aktivering. 
 
Morfologiese veranderinge van M. tuberculosis binne makrofage is beoordeel met behulp van 
elektronmikroskopie. In hierdie manier waarop ons probeer om die lot van M. tuberkulose te volg binne die 
phagosomes, en hoe mycobacteria verwerk word in phagosomes in terme van replikasie, oorlewing en 
agteruitgang. Die vestiging van „n suksesvolle infeksie deur M. tuberculosis hang af van die aanvanklike 
ontmoeting met host makrofage, wat die eerste lyn „n sellulêre verdediging teen mikrobiese inval 
iv 
 
verteenwoordig. Op die grens tussen mycobacteria en makrofage, speel die komplekse buitenste laag van 
die mikobakteriese selwand waarskynlik „n rol in die intog van die gasheersel. 
 
Onder normale omstandighede (dws inname van non patogene mikroörganismes), nuutgevormde 
phagosomes meng inhoud en membraan met die opeenvolgende kompartemente van die endositiese roete 
(vroeë endosomes, laat endosomes, lisosome) deur „n komplekse reeks van samesmelting en fisie. Soos 
hulle verwerk word tot phagolysosomes, ondergaan hulle geleidelike veranderinge deur spesifieke optel en 
verwydering van membraan komponente. Benewens, raak hulle versuur as gevolg van die vacuolair proton 
pomp ATPase geleë in die membraan en verkry giftige bestanddele, insluitend hydrolase wat uiteindelik 
bakterieë vernietig. 
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CHAPTER 1: GENERAL INTRODUCTION AND 
LITERATURE REVIEW  
 
1.1 TUBERCULOSIS: A HISTORICAL PERSPECTIVE  
1.1.1 Current trends in the global epidemiology of TB  
Mycobacterium tuberculosis is the etiological agent for pulmonary tuberculosis (TB) and contributes 
significantly to global mortality (Smith et al, 2004). The estimated worldwide death toll of approximately 
two million deaths every year is attributed to TB and is the highest mortality rate produced by a single 
microorganism (World Health Organisation (WHO) Report, 2010). Robert Koch discovered the M. 
tuberculosis pathogen in 1882, and by that time the disease was common in every part of the world, even in 
Europe (Mathema et al, 2006). TB has been reported to occur since time immemorial, and has been 
documented as one of the oldest diseases affecting man at a large scale today.  
 
The global incidence of TB is predominantly reported in developing countries whose economies are 
characterized by poor incomes and low Gross Domestic Products. Currently TB is prevalent in Africa and 
Asia, and has been closely linked to general poverty and poor hygiene in these regions. The compounding 
association between TB and Human Immunodeficiency Virus (HIV) has aggravated the health situation 
because of disintegrated service delivery systems in the developing world (Zager and McNerney, 2008). 
Africa remains at the fore-front of the global TB epidemic, and the trend has been exacerbated by high 
prevalence of HIV-AIDS co-infection. 
 
One of the most challenging feats that the health sector faces today is total control and eradication of the 
TB epidemic (WHO Report, 2010). The emergence of drug resistant strains of M. tuberculosis has 
complicated efforts directed at combating the disease (Holtz, 2007; Harris et al, 2001). The WHO 2010 
Report recommended that surveillance efforts be extended to allow a forecast of prevalence and incidence 
of M. tuberculosis-resistant strains within a given population.  
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The eradication of TB requires a concerted effort from policy-makers down to the monitoring and 
evaluation of disease cases. Such monitoring of disease patterns requires that Governments dedicate 
significant amounts of their resources to surveillance programmes. One of the United Nations Millennium 
Development Goals (MDG number 6) is to reduce the prevalence of TB infection by 70% through early 
detection intervention strategies by 2015 (Dye and Floyd, 2006). This target, however, seems unrealistic, 
especially in view of the ever-increasing global trends of TB prevalence. 
 
1.1.2 TB control programmes in South Africa 
With the third highest incidence rate and second highest mortality rate in the world, South Africa is facing a 
TB problem of such magnitude that this disease has been declared a national health emergency 
(www.doh.gov.za). The rampant HIV co-epidemic plaguing South Africa has exacerbated the problem 
enormously (Harris et al., 2001) as well as the emergence of multi- and extremely-drug resistant strains 
(MDR-TB and XDR-TB strains, respectively) (Zager and McNerney, 2008).  
 
Although some improvements have been made in controlling TB through reform of existing control 
programs, it is widely acknowledged that a quantum leap in the quality of tools for prevention and 
treatment of TB will be required (if there is to be any hope at all) to eradicate this devastating disease. Of 
all the new and re-emerging infections per annum in South Africa, MDR-TB and XDR-TB strains have 
been estimated at 4.3%, thus further complicating the existing epidemic control efforts.  
 
1.1.3 Spread and transmission of TB 
M. tuberculosis is transmitted from one person to the other when the pathogen is transferred from an 
infected person through air-borne inhalation, which normally occurs during sneezing and coughing (Rhode 
et al, 2007). Transmission of the TB pathogen results in it being taken up by macrophages of the alveoli, 
leading to either its destruction or to an active disease state. When inhaled M. tuberculosis reaches the 
lungs and is phagocytosed by alveolar macrophages to induce a local proinflamatory response which leads 
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to the recruitment of mononuclear cells. (reviewed in de Chastellier, 2009; Russell et al, 2010, figure 1.1 
below).  
 
 
 
1.2 CURRENT ANTI-TUBERCULAR DRUGS AND THE EMERGENCE OF DRUG 
RESISTANT STRAINS  
1.2.1 Anti-tubercular drug interventions: Can TB be fully controlled? 
One of the complications with TB is the latent stage in which the pathogen is either slow-growing or not 
growing at all; this stage is normally resistant to anti-TB drugs. Conventional TB drugs normally target 
biochemical pathways such as cell-wall synthesis and chromosomal replication. Total eradication of TB is 
complicated by those patients who are latently infected, and have the possibility of re-activation of the 
disease (Holtz, 2007). TB treatment drugs consisting of isoniazid (INH), rifampicin (RIF), ethambutol 
(EMB) and pyrazinamide (PZA) have been used as prescription for two months, followed by a continuation 
phase in which only INH and RIF are prescribed. 
 
Figure 1.1: Life cycle of M. tuberculosis 
within the human host and the resultant 
formation of granuloma within the lung. 
When M. tuberculosis is inhaled and gains 
entry into the host via phagocytosis, it 
persists in the macrophages of the lung 
tissues. A sub-population of the infected 
macrophages undergo differentiation, and 
become filled with lipid droplets, referred 
to as foamy macrophages. M. tuberculosis 
eventually escapes when granuloma 
caveates, resulting in transmission to other 
hosts (Adapted from Russell et al, 2010). 
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The emergence of MDR-TB and XDR-TB strains that are resistant to the existing drug regimen has posed 
serious challenges to the global control and eradication of TB (Zager and McNerney, 2008). Hoek et al 
(2008) defined MDR-TB as: “… disease caused by M. tuberculosis that is resistant in vitro to both 
isoniazid and rifampin with or without resistance to other anti-TB drugs.” According to Holtz (2007), 
XDR-TB is: “…the occurrence of TB in persons whose M. tuberculosis isolates are resistant to isoniazid 
and rifampin plus any fluoroquinolone and at least one of the three injectible second-line drugs (amikacin, 
kanamycin, capreomycin)”.  
 
1.2.2 Mechanisms of action of first-line TB drugs and the evolution of antibiotic resistance  
When administered into a patient, INH causes the infecting mycobacteria to undergo alterations in the cell 
wall structure such as the disruption of internal organization, development of wrinkles on the surface as 
well as buldging (Zager and McNerney, 2008). Such ultrastructural alterations have been confirmed by 
electron microscopy examination of M. tuberculosis upon exposure to INH (Takayama et al, 1973). In 
addition, INH effects a loss in the property of mycobacteria known as acid fastness (Takayama et al, 1972; 
Vilcheze et al, 2000). Precise mechanisms by which INH induces ultrastructural distortions of internal 
organization are still under investigation, 50 years after its discovery as an anti-mycobacterial agent.  
 
Antibiotic resistance genes code for defense strategies through which bacteria survive in an environment 
where there are antibiotics that are supposed to be inhibiting bacterial growth. Several mechanisms have 
been suggested to play a role in conferring antibiotic resistance (Al-Haroni, 2008), and these include 
structural alteration of the target molecules, cellular exclusion and drug efflux. Mycobacteria have 
developed mechanisms through which antibiotics are inactivated through enzymatic action. A typical 
example is the expression of β-lactamases which degrade the β-lactam antibiotics, thereby conferring drug 
resistance (van Bambeke et al, 2000).  
 
Drugs such as INH and RIF have been used in combination to fight TB for a long time, but the emergence 
of drug resistant TB strains prompted researchers on the urgent need to develop and test the efficacy of 
other drug formulations. INH is a pro-drug that functions through its intermediates to block pathways 
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involved in mycolic acid biosynthesis. Treatment of TB with INH therefore, is based on its ability to inhibit 
the biosynthesis of mycolic acids, long chain fatty acids which make up the bulk of mycobacterial cell wall, 
killing the pathogen in the process (reviewed by Vilcheze and Jacobs, 2007). Different genes encoding for 
drug resistance in M. tuberculosis have been characterized, and gene knockout mutants have been used to 
gain further knowledge on the molecular mechanisms that underlie these processes as shown in Table 1.1 
below (Sharma and Mohan, 2004, Vilcheze et al, 2008).  
 
Table 1.1: Anti-tuberculosis drugs and the gene(s) involved in their susceptibility in M. tuberculosis. 
Mutations in the indicated genes confer resistance to generic antibiotics that are normally effective as first 
line defense drugs. In cases of MDR-TB and XDR-TB, mycobacteria become resistant to more than two 
antibiotics due to concurrent expression of these genes.  
 
Drug      Mutations in these genes result in drug resistance 
 
Isoniazid     Enoyl acp reductase (inhA) 
Catalase-peroxidase (katG) 
Rifampicin     RNA polymerase subunit B (rpoB) 
Pyrazinamide     Pyrazinamidase (pncA) 
Streptomycin     Ribosomal protein subunit 12 (rpsL) 
16s ribosomal RNA (rrs) 
Aminoglycoside phosphotransferase gene (strA) 
Ethambutol     Arabinosyl transferase (emb A, B and C) 
Fluoroquinolones    DNA gyrase (gyr A and B) 
 
 
Adapted from Sharma and Mohan, (2004) 
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INH  is the most important antimicrobial agent that has been used in the treatment of M. tuberculosis. 
When M. tuberculosis is exposed to INH, the mycolic acid pathway is inhibited, leading to the 
accumulation of fatty acids and eventually cell death (Vilcheze and Jacobs, 2007). The activation of INH is 
accomplished through the activity of catalase-peroxidase katG which results in the formation of an 
isonicotinoyl radical. The activated INH reacts with NAD, forming an INH-NAD adduct which inhibits the 
FASII enoyl-ACP reductase inhA (Vilcheze et al, 2000). The inhibition of FASII inhA leads to cell death of 
the M. tuberculosis.  
 
Mutations in catalase-peroxidase katG have been reported to be critical in conferring drug resistance in M. 
tuberculosis (Johnson, 2007). These mutations in katG have been observed to prevent the formation of 
INH-NAD complex. The sub-cellular location of the INH-NAD adduct also needs to be established in an 
effort to develop effective drugs against M. tuberculosis. Several gene mutations have been implicated in 
the INH resistance mechanisms, but the dominant phenotype mutations are due to inhA while other 
mechanisms of resistance such as katG, msh, nat and ndh have been found to be recessive (reviewed in 
Figure 1.2: Pathways inhibited by first 
line drugs against M. tuberculosis. 
 
In this illustration, PYZ = pyrazinamide, 
INH = isoniazid, and RIF = rifampicin, 
ETB = ethambutol are drugs that target 
different pathways that are essential for 
the survival of M. tuberculosis (adapted 
from du Toit et al, 2006).  
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Vilcheze and Jacobs, 2007). As more studies on M. tuberculosis drug resistance continue, attempts have 
been made to identify alleles for resistance and their possible mechanisms of action.  
 
1.3 SURVIVAL STRATEGIES OF M. tuberculosis WITHIN HOST MACROPHAGES  
1.3.1 Entry of M. tuberculosis into the host macrophage 
The establishment of a successful infection by M. tuberculosis depends on the initial encounter with host 
macrophages, which represent the first line of cellular defense against microbial invasion. Ingestion of 
mycobacteria occurs through a receptor-mediated, actin-dependent process called phagocytosis. At the 
interface between mycobacteria and macrophages, the complex outermost layer of the mycobacterial  cell 
wall probably plays a role in facilitating host cell entry. Several envelope molecules have been shown to 
interact with macrophage phagocytic receptors (Astarie-Dequeker et al, 2009). For instance 
lipoarabinomannan binds to the mannose receptor which is one of the major receptors for mycobacterial 
entry (Schlesinger et al, 1994). Another important phagocytic receptor of macrophages, the complement 
receptor 3, recognizes outer mycobacterial capsular polysaccharides through its lectin site.  
 
1.3.2 Survival of M. tuberculosis occurs via arrest of phagosome maturation 
Under normal conditions (i.e. ingestion of non pathogenic microorganisms), newly formed phagosomes 
intermingle contents and membrane with the successive compartments of the endocytic pathway (early 
endosomes, late endosomes, lysosomes) through a complex series of fusion and fission events (shown in 
figure 1.3, Vieira et al, 2002). As they are processed into phagolysosomes, they undergo gradual 
modifications by specific addition and removal of membrane constituents. In addition, they become 
acidified due to the vacuolar proton pump ATPase located in the membrane and acquire toxic constituents, 
including hydrolases that will ultimately destroy bacteria. One of the major strategies used by endoparasites 
such as pathogenic mycobacteria, but by no means the only one, is to modulate these interactions. 
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 A striking feature of M. tuberculosis is its ability to prevent maturation of the phagosome in which it 
resides. In this manner, it avoids the acidic and hydrolytically active phagolysosome compartment 
(Armstrong and Hart, 1971; Clemens and Horwitz, 1995; de Chastellier et al., 1995; Via et al., 1997). 
Recently, de Chastellier and colleagues have shown that a necessary requirement for the block of 
phagosome maturation is the establishment of a close apposition of the phagosome membrane with the 
entire mycobacterial surface all around (de Chastellier and Thilo, 1997; 2006; de Chastellier et al, 2009).  
 
1.3.3 Intracellular responses and rescue mechanisms from hostile internal environment 
Work done by de Chastellier (2009) suggests that, whatever the molecular mechanisms involved in the 
block of maturation of the mycobacterium-containing phagosome, a necessary requirement is the 
establishment and maintenance of a close apposition of the phagosome membrane with the entire bacterial 
surface all around (de Chastellier and Thilo, 1997; Pietersen et al, 2004; de Chastellier and Thilo, 2006). 
Whenever several mycobacteria are enclosed in the same phagosome, close apposition is not maintained in 
Figure 1.3: Phagosome maturation (adapted from Vieira 
et al, 2002).  
 
In this illustration, pathogenic bacteria are engulfed 
from the cell surface and channelled through a series of 
maturation stages until the final fusion with lysosomes. 
Within the endocytic pathway, there is continuous 
exchange of membranes and membrane contents 
through fusion and fission events. Actin is important in 
the endocytic pathway, and is found in abundance at the 
phagocytic cup. Abbreviations used in this figure: CCV 
= clathrin-coated vesicle; EV = endocytic vesicle; SE = 
sorting endosome; LE = late endosome; LY=  lysosome; 
ER = endoplasmic reticulum. 
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the regions where the phagosome membrane spans adjacent bacteria. Such phagosomes systematically 
mature and fuse with lysosomes (de Chastellier et al., 1995; Clemens and Horwitz, 1995; de Chastellier and 
Thilo, 1997; Pietersen et al., 2004). Interestingly, mycobacteria do not die in this hostile environment but 
are instead rescued by a process that remains to be determined (de Chastellier, 2009).  
 
1.4 MYCOTHIOL, A POTENTIAL TARGET FOR NEW ANTI-TUBERCULAR 
DRUGS 
1.4.1 Genetic control of mycothiol biosynthesis in M. tuberculosis 
A wide variety of bacterial constituents that play an important role in the pathogenicity of M. tuberculosis 
could be potential targets for novel therapeutic strategies. Mycothiol has recently emerged as a potential 
candidate because it performs critical functions within mycobacteria.  Mycothiol is a major low molecular 
weight thiol present in a wide range of actinomycetes, and protects mycobacteria  against oxidative stress 
(Newton et al, 1996). It acts as an antioxidant by reacting with exogenous or endogenous reactive oxygen 
intermediates, thereby maintaining an intracellular redox homeostasis (Dosanjh-Nirpjit et al, 2005). During 
this reaction, two equivalent mycothiols are oxidized to one molecule of mycothiol disulfide (MSSM).  
 
Mycobacteria produce mycothiol at very low levels of up to milli-molar per mL quantities, and the 
biosynthesis of mycothiol occurs via five gene-controlled stages (Rawat et al, 2003). The genes that code 
for the proteins involved in the mycothiol pathway are designated mshA, mshA1, mshB, mshC and mshD, 
coding for glycotransferase, deacetylase, ligase, and acetyltransferase, respectively (Newton and Fahey, 
2002; figure 1.4). The formation of GlcNAc-Ins is the first key step, regulated through the expression of 
mshA (Rv0486), which codes for the enzyme N-acetylglucosamine transferase (Anderberg et al, 1998).  
 
The second step in mycothiol biosynthesis is regulated by the mshB gene (Rv1170) which codes for a de-
acetylase which results in the removal of the acetyl group from N-acetylgulcosamine, resulting in GlcN-Ins 
(Fan et al, 2009). The third step is the ligation of cysteine with GlcN-Ins though the action of a ligase 
coded for by mshC (Rv2130c). Mycothiol is finally formed through the acetylation of Cys-Glc-Ins, a 
reaction controlled by MshD acetyltransferase (Rv0819) (Newton et al, 2008). M. tuberculosis gene 
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knockout mutants and recombinants of mycothiol biosynthesis genes and related proteins have been studied 
(Park et al 2006), and have helped understand mycothiol biosynthesis and regulation. 
 
Figure 1.4: The pathway for biosynthesis, recycling of mycothiol and detoxification of xenobiotics 
(adapted with permission from Vilcheze et al, 2008). 
 
Enzymes involved in mycothiol metabolism were chosen as attractive targets for designing new 
antituberculous drugs because most of these enzymes and in particular, MshC is essential for M. 
tuberculosis survival (Fan et al, 2009). In contrast however, inactivation of MshB is non-lethal since the 
Mycothiol S-conjugate amidase (Mca) production of GlcN-Ins (1-D-myo-inosityl-2-amino-2-deoxy-alpha-
D-glucopyranoside) results in the mycobacteria still being able to synthesize MSH and survive (Rawat et 
al, 2003). Inactivation of mycothiol reductase inhibits the growth of M. tuberculosis (Sassetti et al, 2003; 
Hayward et al, 2004).  
 
In order to develop new drugs through rational drug design, we analysed the expression of all important 
enzymes of the mycothiol pathway. We postulated that mycothiol biosynthesis drug targets may be 
important for the treatment of tuberculosis since mycothiol and MSSM establish a thiol buffer system in 
mycobacteria. Gene knockout studies done on M. tuberculosis Erdman mycothiol genes (Sareen et al, 
2003) have suggested that mshC is a potentially good candidate for drug targeting.  
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1.4.2 Biochemistry of mechanisms involved in the mycothiol pathway  
Within the intracellular environment, mycothiol protects the cell against antibiotics, electrophiles and other 
reactive substances which react with the thiol groups (Fan and Blanchard, 2009). In the presence of 
antibiotics or under electrophilic attack, the mycothiol-S-conjugate is degraded to produce GlcN-Ins which 
will then help to recycle mycothiol for cellular defense (Jothivasan and Hamilton, 2008). The mycothiol 
pathway is closely regulated through the action of the mycothiol reductase enzyme, Mtr that helps to 
maintain the reduced form, MSH (Patel and Blanchard, 1999).  
 
The gene that codes for the mycothiol reductase enzyme has been identified (Newton and Fahey, 2002) and 
cloned, and has been found to be very similar to glutathione oxidoreductase. Mycothiol is involved in the 
replenishment of cysteine, another anti-oxidant molecule found in mycobacteria. A pathway in which 
cysteine is regenerated from mycothiol has been proposed by Anderberg et al (1998), and has been shown 
to suggest that acetyl-cysteine is converted to cysteine. Mycothiol functions as a protective molecule 
against reactive oxygen species within actinomycetes, and the conjugation of two MSH molecules results in 
MSSM. Mtr activity helps maintain a high MSH:MSSM ratio through the reduction of MSSM to MSH. 
The activity of Mtr depends on NADH and NADPH as reducing cofactors, but NADPH is more effective 
as a substrate, with >20 fold greater kcat/km value than NADH (Jothivasan and Hamilton, 2008). 
 
Mycothiol-S-conjugate amidase is utilized by actinomycetes to detoxify the reactive oxygen species and 
other toxins through hydrolysis of glucosaminyl-amide bond of MS-congugates to release the mercapturic 
acid-labeled toxin and GlcN-Ins (Jothivasan and Hamilton, 2008). Mycothiol-S-conjugate amidase (Mca) is 
a zinc-dependent N-acyl hydrolase that is closely related to MshB. Studies have been done with 
monobromobimane (mBBr), a fluorescent alkylating agent that forms an adjunct that is degraded by Mca, 
producing mercapturic acid (AcCyS-mB) and GlcN-Ins (Rawat et al, 2004). The mercapturic acid 
derivatives are excreted from the cell while GlcN-Ins is recycled back to the MSH biosynthetic pathway. 
Although the mycothiol-Mca relationship has been proposed as important in the detoxification and eventual 
efflux of mBBr, it is the mycothiol rather than Mca that has been found to be critical for the detoxification 
process. 
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Mca is the most important enzyme in the bio-inactivation of electrophilic molecules as well as the reactive 
oxygen species within the mycothiol pathway. Mca is important in the cleavage and subsequent 
dissociation of mercapturic acid from GlcN-Ins.  The role of amidase was confirmed by experimental 
evidence (Rawat et al, 2004) that mca gene knockout mutants become more prone to antibiotics when 
compared to the wild-type. However, not all antibiotics are dependent on amidase activity, for example 
lincomycin has a gene homologous to the mca in its antibiotic biosynthesis cluster.  
 
Vilcheze et al (2008, and unpublished data) have been able to knockout all the genes involved in the 
mycothiol pathway in M. tuberculosis, except for the mshC gene. The inability to successfully generate a 
deletion gene knock-out studies suggests that mshC is important for M. tuberculosis growth. In fact, based 
on these results, one would hypothesize two alternative explanations for the inability to delete mshC gene 
in M. tuberculosis: (1) the mshC gene is part of some other essential pathway or (2) mshC inactivation leads 
to the accumulation of some toxic intermediate (Jacobs, personal communication).  The mshB and mshD 
genes are not essential for M. tuberculosis as mutants in these genes still produce significant amounts of 
MSH or related thiols. Mycothiol-deficient bacteria show increased resistance to INH, and this resistance 
has been used as a selection marker when screening for mutants in mycothiol biosynthesis (Rawat et al, 
2007). Resistance to ETH is also enhanced in MSH-deficient mutants. INH and ETH are both pro-drugs 
requiring catalase peroxidase (katG) and flavoprotein mono-oxygenase activity respectively.  
 
Jothivasan and Hamilton (2008) acknowledge findings by Vilcheze et al (2008) that demonstrate the 
possibility of generating MSH-deficient strains of M. tuberculosis, which grow normally in immuno-
deficient mice and only show slight defective growth in immuno-competent mice. However Vilche`ze et al 
(2008) suggest that MSH is not essential for in vivo growth of M. tuberculosis in mice. The work reported 
herein argues that on the basis of the findings by Vilche`ze et al (2008) it would be worthwhile to 
investigate how MSH-deficient M. tuberculosis survives in vivo when exposed to anti-TB drugs.  
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1.5 HYPOTHESIS  
New anti-tubercular drugs have been designed towards inhibition of specific steps of the mycothiol 
pathway and its intermediates. The ability of mycobacteria to survive within the host is may depend on 
mycothiols which confer protection against reactive oxygen species that would otherwise disrupt cellular 
functions (Raman et al, 2005). In this regard, the design of drugs against TB has focused on the mycothiol 
biosynthetic pathway (figure 1.4) with a view to understand the genetic and molecular mechanisms 
underlying the process of mycobacterial survival within the macrophages. 
 
Our hypothesis was that a drug inhibiting the expression of mshA affects synthesis of mycothiol. In the 
absence of mycothiol, the bacilli are killed as they cannot resist reactive oxygen species and reactive 
nitrogen intermediates generated during oxidative stress. Ultimately, this would affect the ability of M. 
tuberculosis treated with drugs against mycothiol to block phagosome maturation. M. tuberculosis-
containing phagosomes would then be processed into phago-lysosomes in which bacilli would be degraded. 
We targeted mycothiol enzymes as the production of mycothiol has been implicated in reducing multidrug 
resistance (Jardine, personal communication). The development of inhibitors that target mycothiol 
biosynthetic or processing enzymes has been postulated to constitute important approaches towards 
improving tuberculosis treatments. 
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CHAPTER 2: DRUG TESTING AND MYCOTHIOL 
QUANTITATION ON IN VITRO GROWING M. tuberculosis  
2.0 INTRODUCTION  
Compounds that inhibit the biosynthesis of mycothiol were developed in the context of this study, and 
would potentially serve as useful agents for TB treatment. The fact that genes involved in mycothiol 
pathway have been characterized (Hayward et al, 2004; Park et al, 2006; Sassetti et al, 2003), and several 
studies on their expression and function have been reported (Patel and Blanchard, 1998; Takayama et al, 
2005) means that enzyme-specific inhibitors of this pathway could be developed.   
 
Drug screening experiments were initiated by obtaining the purified mshA enzyme to assay for compound 
binding activities (Jardine Lab, University of Cape Town, South Africa). Since all enzymes within the 
mycothiol pathway use substrates with the same basic structure, compounds that showed adequate binding 
and inhibitory activity in the enzyme assay were further derivatised and screened for mycobacterial killing 
effects. The role of mycothiol for the survival of M. tuberculosis was also investigated by using the mshA 
deletion mutant. The phenotype of the mshA deletion mutant of M. tuberculosis was investigated by 
exposing the mycobacteria to INH, arsenic (V) acid and different culture media compositions. 
 
The objective of this work was to test inhibitors of enzymes of the mycothiol pathway and derivatives 
thereof in the BACTEC 460
TM
 system. Furthermore, assays were validated by using substrate mimetics as 
inhibitors. These substrate mimetics were synthesised in a linear fashion from available starting materials. 
Some commercially available natural product substrate analogs (such as busulfan) were also tested for 
inhibitory activity. A library of drug-like compounds was synthesised and tested (figure 2.6). 
 
2.1 MATERIALS AND METHODS  
2.1.1 Culturing of M. tuberculosis 
M. tuberculosis H37Rv strain were cultured in 7H9 broth supplemented with 10% oleic acid-albumin-
dextrose catalase
 
(OADC, Difco, BD Biosciences, Mountain View, CA, USA) and 2% glycerol and
 
0.05% 
- 15 - 
 
Tween 80.
 
Liquid cultures were grown for up to 3 weeks and stored at -80°C
 
in 1ml aliquots with 15% 
glycerol. Clumps were eliminated after thawing by 25 to 30 passages through a needle (26-gauge 3/8;
 
0.45 
x 10 for intradermal injection; BD Biosciences, USA). Before
 
inoculation, the viability of mycobacteria, 
was evaluated by the propidium
 
iodide exclusion method to ensure >90% viability (Pietersen et al, 2004).  
 
2.1.2 Stress conditions for mycothiol production in M. tuberculosis  
A pre-culture of M. tuberculosis (5 mL) was incubated at 37
o
C for 3 weeks. Experimental cultures (25 mL) 
were inoculated with the pre-culture of M. tuberculosis and incubated for 7 days at 37ºC after which 
stress/drug interventions were done. INH was added to induce stress to M. tuberculosis (at 0.2 and 2 µg/mL 
for H37Rv and INH
R
, respectively), and samples were processed at 0 hr, 4 hr, 24 and 48 hr post-drug 
exposure.  Mycothiol produced after exposure of M. tuberculosis to stress conditions of INH was quantified 
via LC-MS triple quadpole analysis. 
 
2.1.3 Mycothiol extraction methods from M. tuberculosis 
Two different extraction methods were used to obtain mycothiol from in vitro growing M. tuberculosis 
under stress conditions as follows:  
(i) Sonication with perchloric acid/acetonitrile/water 
Steenkamp and Vogt (2004) used this method to purify mycothiol from M. smegmatis. In brief, cells were 
disrupted through sonication, and mycothiol was extracted using a buffer system of 0.25M perchloric acid 
and 2mM EDTA in a 40% acetonitrile/H2O. After removal of the cell debris, the supernatant was directly 
lyophilized overnight. The resulting residue was re-suspended in 50% acetontrile/H2O before LC-MS 
analysis.  
(ii)  BugBuster® extraction method 
BugBuster
®
 protein extraction reagent (Novagen, Germany) was also used to extract the analytes. Cell 
pellets were re-suspended in five times less extraction buffer than the original culture sample. The 
suspensions were incubated for 2 hours at room temperature on a shaking platform. The cell debris was 
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removed through centrifugation and the supernatant lyophilized overnight. The remaining residue was re-
dissolved in 50% acetonitrile/H2O and processed for LC-MS analysis.  
 
2.1.4 Determination of mycothiol levels by LC-MS analysis 
Both mycothiol (MSH, reduced form) and mycothione (MSSM, oxidised form) that were used as standards 
for mycothiol quantitation via LC-MS were kindly donated by Professor Spencer Knapp from the 
Department of Biology and Chemistry at Rutgers The State of New Jersey University in the United States 
of America. LC-MS analysis was performed at the Mass Spectrometry Unit of the Central Analytical 
Facility (www.sun.ac.za/caf), University of Stellenbosch. Samples were analyzed on an ACQUITY UPLC
® 
system (Waters Corp., USA) with an autosampler and a Synergi 4 μM Fusion RP, 250x2mm column 
(Phenomenex). The sample injection volume was 20 μl and the auto sampler syringe was washed with 
solvent A (0.1% formic acid in water) before each injection. A gradient elution program with a flow-rate of 
0.20 ml/min was used for the analysis. The gradient was as follows: 100% solvent A for 8 min; 7 min linear 
increase up to 95% solvent B (0.1% formic acid in acetonitrile); 95% B step for 3 min; 95% solvent A from 
18 to 20 min.  
 
Detection of mycothiol (MSH and MSSM) was performed on a Q-TOF Ultima API quadrupole mass 
spectrometer (Micromass, Manchester, UK). Analytes were detected in the positive ion mode. The capillary 
voltage was set at 3500 V. The source temperature and the nebulization gas temperature were set at 80 ºC 
and 250 ºC, respectively. The cone voltages were set at 35V. Data was processed using MassLynx™ 
software (Micromass, Manchester, UK). All statistical data analysis and graphical presentation of the data 
was performed with Microsoft
®
 Office Excel 2007. 
 
2.1.5 Sensitivity tests of WT and ∆mshA deletion mutants of M. tuberculosis  
M. tuberculosis gene knockout mutants deficient in mshA gene were kindly provided by Dr Catherine 
Vilcheze from Albert Einstein College of Medicine in the USA.  In this study, the role of growth conditions 
and media composition on the survival of wild-type vs the ∆mshA strain was investigated. Furthermore the 
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phenotypic responses of the WT vs the ∆mshA strain were investigated by exposure to INH (0.01, 0.05 and 
0.1 µg/mL) and arsenic (V) acid (1mM, 50mM and 100mM). The plates were incubated for periods up to 4 
weeks at 37
o
C until colonies appeared.  
 
2.1.6 Monitoring M. tuberculosis growth in the presence of inhibitors of the mycothiol pathway via 
BACTEC 460™ system 
M. tuberculosis H37Rv (1 mL aliquots) were thawed and grown directly in BACTEC
 
460
™
 vials with 
various concentrations of inhibitors (between 0 and 10 µg/mL). The inhibitors tested in this study were 
mainly directed towards the mshA enzyme of the mycothiol pathway. M. tuberculosis was cultured for 7 
days before addition of inhibitors of mycothiol enzymes and BACTEC 460
TM
 measurements. Untreated M. 
tuberculosis was grown under the same conditions to serve as a control. Mycobacterial growth was 
monitored
 
by the BACTEC
 
460
™
 instrument which makes use of radioactively labelled 
14
C 
triacylglycerides (Roberts et al, 1983). The minimal inhibitory concentrations for the drugs were calculated 
based on BACTEC 460
TM
 growth index readings.  
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Quantitation of mycothiol via quad-pole LC-MS  
 
In this work, mycothiol expression was quantified via LC-MS after M. tuberculosis was exposed to 
oxidative stress induced by INH. The mycothiol peaks were integrated to provide an indication of the 
amounts in each sample relative to one another (refer to Table 2.1 below). Mycothiol was maximally 
produced during the early time points (4 hours after drug exposure in this case) as this would allow the 
pathogen to survive and adapt to the conditions of stress. The levels of mycothiol (and its intermediates) 
have previously been determined for M. tuberculosis and M. smegmatis as a function of the growth phase 
(Anderberg et al, 1998). The levels of MSH have been found to be constant through the exponential growth 
and stationary phase. During the stationary phase, there appeared to be a significant drop in the 
intermediates i.e. GlcN and GlcN-Ins, and an increase in H2S levels (data not shown). In this study 
mycothiol levels were found to be around 80% in the M. tuberculosis H37Rv strain during the early 
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exponential phase, and dropped slightly to around 70% in the stationary phase upon exposure to INH (at 
0.2 µg/mL).  
 
Table 2.1: Changes in mycothiol levels over the growth phase. Table summarises mycothiol levels after 
different treatments of M. tuberculosis upon exposure to INH (at 0.2µg/mL) for different time points (4 hrs, 
24 hours and 48 hrs). Mycothiol was extracted as described in the Materials and Methods section (sections 
2.1.3), and quantified via LC-MS using the triple quad-pole method (described in section 2.1.4).  
Sample ID M. tuberculosis strain  INH 
concentratio
n (µg/mL) 
Time of drug 
exposure/hrs 
% mycothiol  
A M. tuberculosis Beijing INH
R
 - control  - control 49.1 
B M. tuberculosis Beijing INH
R
  0.2 µg/mL 4 hrs 46.9 
C M. tuberculosis Beijing INH
R
 0.2 µg/mL 24 hrs 47.4 
D M. tuberculosis Beijing INH
R
 0.2 µg/mL 48 hrs 52.7 
E M. tuberculosis H37Rv 0.2 µg/mL 4 hrs 84.1 
F M. tuberculosis H37Rv  0.2 µg/mL 24 hrs 70.5 
G M. tuberculosis H37Rv 0.2 µg/mL 48 hrs 72.7 
 
Mycothiol levels were followed over the growth phase in the Beijing INH
R
 strain and was found to be half 
the levels in the M. tuberculosis H37Rv strain (between 40 – 50%) at INH 0.2 µg/mL. If this data is 
corroborated with INH resistance phenotype of the mshA of M. tuberculosis, this might suggest that the 
Beijing INH
R
 strain had a defect in mycothiol expression. Mycothiol levels were found to be in the same 
range for M. tuberculosis Beijing INH
R
 strain at INH concentration of 2µg/mL (data not shown).  
Mycothiol quantitation was done by following the levels of the oxidised form (since this is the predominant 
form in which mycothiol exists in the cell). The equilibrium between reduced and oxidised forms of 
mycothiol is maintained by mycothionine reductase system; during conditions of oxidative stress MSSM is 
actively reduced to MSH which scavenges for free radical generated from antibiotics, ROI or RNI within 
the environment.  
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Figure 2.1: LC-MS quantitation of mycothiol levels in M. tuberculosis H37Rv and Beijing INH
R
 at 
different time points after treatment with INH using different concentrations. Figures on the left (A - G) are 
chromatograms showing extraction of mycothiol in the H
+
 ion mode at m/z = 971 (shown by red arrow on 
the chromatograms), and figures on the right (A1 - G1) are integrated chromatograms showing relative 
amounts of mycothiol as percentage points.  
 
In this study mycothiol levels were quantified via LC-MS and shown to increase under antibiotic stress 
conditions. Mycothiol confers protection against reactive oxygen species and electrophiles to mycobacteria 
(Anderberg et al, 1998). The effect of electrophilic moieties and reactive oxygen species on cellular 
antioxidant status is that they destroy the biological integrity of the molecules through disruption of S-
groups in proteins and DNA base-pairing. In the mycothiol pathway, the reverse reaction which maintains a 
constant MSH:MSSM ratio is catalyzed by mycothiol disulfide reductase which is encoded by the Rv2855 
(mtr) gene (Patel and Blanchard, 1998). As for other functionally homologous enzymes such as glutathione 
and trypanothione reductase, it depends on bound FAD and NADPH for the reduction of the disulfide bond 
of MSSM to produce two equivalents MSH (Patel and Blanchard, 1999). Interestingly, mycothiol and the 
enzymes involved in its metabolism are sensitive to free radical generating antituberculosis drugs (This 
study; Hayward et al, 2004).  
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2.2.2 Mycothiol mutants (∆mshA)  grow poorly/do not grow on 7H9 without OADC 
Growth on solid plates indicated that the ∆mshA mutant required OADC supplement to grow (figure 2.2). 
Vilcheze et al (2008), investigated the same phenomenon, and implicated catalase as a prerequisite for the 
survival of the ∆mshA mutant. It would be interesting, however, to investigate how the ∆mshA strain would 
survive when first grown in the presence of catalase (up the late log-phase, for example), then remove the 
catalase from the growth media. In this way, the requirement for catalase for the survival of the ∆mshA 
strain would be ascertained.  
 
 
Figure 2.2: Growth of WT M. tuberculosis H37Rv and the ∆mshA gene knock-out mutant of M. 
tuberculosis H37Rv on solid media of Middlebrook 7H10 agar supplemented with 0.2% glycerol and 
OADC, AC, DC, ADC  and ADS. [A = albumin, O = oleic acid, D = dextrose S = sodium chloride and C = 
catalase]. 
 
The mshA strain did not grow in the presence of ADS (bovine albumindextrose-sodium chloride), but grew 
normally under OADC supplementation. Catalase has been implicated in the detoxification of any reactive 
oxygen species or peroxides in the growth media. Mycothiol is important in detoxification, hence its 
absence in the mshA mutant explains the poor/no growth in the absence of catalase within the growth 
- 23 - 
 
media. Vilcheze et al (2008) hypothesised that (i) the mouse in vivo environment was not conferring 
significant oxidative stress or (ii) that the in vivo environment resulted in the production of other thiols that 
compensated the absence of mycothiol. Since Vilcheze et al (2008) had reported that mshA was not 
essential in vivo, we sought to generate the mshC conditional deletion mutant in M. tuberculosis (on-going 
project, data not reported herein).  
 
2.2.3 Mycothiol mutants (∆mshA) are resistant to INH 
The mshA gene knockout mutant was used to investigate the phenotype in the presence and absence of 
conditions of stress, such as INH (see figure 2.3).  
 
(A)                                         (B)                                             (C) 
Figure 2.3: Sensitivity tests of M. tuberculosis H37Rv and ∆mshA to INH. In this figure, wild type (WT) 
M. tuberculosis H37Rv and the ∆mshA gene knock-out mutant of M. tuberculosis H37Rv were cultured on 
solid media of Middlebrook 7H10 agar supplemented with 0.2% glycerol and OADC. INH was added at 
different concentrations: (A) 0.01 µg/mL, (B) 0.05 µg/mL and (C) 0.1 µg/mL.  
 
 As shown in figure 2.3 above the mshA deletion mutant of M. tuberculosis was resistant to INH at 
concentrations which inhibited growth of the WT. At 0.1 µg/mL INH ∆mshA still survived, but the growth 
of the WT was significantly reduced. Vicheze et al (2008), investigated this resistance mechanism, and 
proposed that mycothiol was required for the activation of the katG and inhA in M. tuberculosis. The mshA 
deletion mutant of M. tuberculosis is defective in mycothiol production, and in the absence of mycothiol M. 
tuberculosis became resistant to antibiotics due to reduced activities of both katG and inhA.  
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2.2.4 Mycothiol mutants (∆mshA) are resistant to arsenic (V) acid  
The importance of arsenate resistance in this investigation dates back to one of the oldest known antibiotic, 
Salvarsan 606 which was based on the toxicity of arsenic acid. In M. tuberculosis arsenate reductases 
(important for protection against arsenate) use mycothiol and mycoredoxin in a thiol/disulfide redox 
cascade (Ordo´nez et al, 2009). Enzymes involved in mycothiol biosynthesis as well as these arsenate 
reductases have been suggested to be involved in arsenate resistance.  
 
In this work, we used the ∆mshA mutant to investigate resistance patterns to arsenic acid (V). Indeed, the 
mshA strain showed increased resistance to arsenic acid (V) vs the WT strain (figure 2.4). Reduction of 
arsenate (V) to arsenite (III) is catalysed by arsenate reductase. The role of mycoredoxin is to reduce the 
thiol-arseno bond and form arsenite and mycothiol-mycoredoxin mixed disulphide. Mycoredoxin is then 
recycled by a second molecule of mycothiol, resulting in the formation of reduced mycothiol (MSSM) that, 
in turn is reduced by mycothionine reductase (model for this system is shown in figure 2.5).  
 
 
 
Figure 2.4: Growth of wild type (WT) M. tuberculosis H37Rv and the ∆mshA gene knock-out mutant of M. 
tuberculosis H37Rv on solid media of Middlebrook 7H10 agar supplemented with 0.2% glycerol and 
OADC. Arsenic acid (V) was added different concentrations of 1 mM, 50 mM and 100 mM. 
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Figure 2.5: The proposed link between mycothiol pathway and the mycoredoxin system, and resistance 
mechanisms to arsenate. In this illustration, Mrx = mycoredoxin system, MSH = reduced mycothiol, 
MSSM = oxidised mycothiol, mtr = mycothionine reductase, Trx = thioredoxin system, Red = reduced 
form, Ox = oxidised form.  
 
In further work it would be desirable to assess how the mshA gene-knockout would behave within infected 
macrophages, and then analyse replication/survival/death of this strain via electron microscopy and colony 
forming unit counts. Although the BACTEC 460
TM
 assay was used in this study, colony forming units 
would be useful to investigate M. tuberculosis survival after treatment with different inhibitors over time 
 
2.2.5 Synthesis of drugs against enzymes of the mycothiol pathway  
All the inhibitors and drug-like compounds directed against enzymes of the mycothiol pathway 
(specifically mshA) were synthesised by Dr Anwar Jardine at the University of Cape Town in South Africa. 
Expression and purification of enzymes crucial to the mycothiol pathway as well as subsequent enzyme 
inhibition tests were done at the University of Cape Town. In order to inhibit mshA (a glycosyltransferase 
involved in the first step of mycothiol biosynthesis), the substrate analogs of uridine diphosphate-N-acetyl 
glucosamine, UDP-GlcNAc (URID) were synthesised in a total of 10 steps from glucosamine. Likewise, 
the dipolar addition product of a thiopropargyl group and azide, gave the “CLICK” substrate analog in a 
total of 12 steps from glucosamine and uridine respectively.  Commercially available substrate analogs 
were also required for testing (structures shown in figure 2.6). The most active compounds that were 
selected include the known glycosyl transferase inhibitors, nikkomycin (AJ7) and tunicamycin (AJ-8). 
Red Mrx1  Ox Mrx1 
 
 
 
 
2MSH    MSSM 
 
 
            MTR 
 
NADPH   NADP 
 
Red Mrx2  Ox Mrx2 
Red Trx   Ox Trx 
 
                  TrxR (trxB) 
 
 
 
NADPH   NADP 
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Figure 2.6: Structures of compounds that were tested in this study for anti-tubercular activity with specific 
reference to mycothiol biosynthesis. 
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Figure 2.2: Structures of inhibitors tested for in vitro inhibition of growth in M. tuberculosis, specifically 
focussing on enzymes of the mycothiol pathway.   
 
Figure 2.7: Structure of inhibitors of mycothiol enzymes that were tested on in vitro growing cultures of M. 
tuberculosis.  
 
 
The treatment of aldehydes with rhodamine and rhodamine-3-acetic acid gave a library of compounds. 
Thiazolidinone scaffold is known to demonstrate widespread biological activity. The thiazolidine 3-acetic 
acid library was further coupled to URID to give a series of relatively stable, active ester intermediates, 
T1A-T12A. Longer reaction times of the T1A – T12A series of inhibitors gave less active compounds T1C-
T12C as shown by extracellular activities in figure 2.9. 
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Figure 2.8: Structures of inhibitors of mycothiol enzymes that were tested on in vitro growing cultures of 
M. tuberculosis.  
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Figure 2.9: Structures of inhibitors derived from longer reaction times of the thiazolidine 3-acetic acid 
library (T1A - T12A series of inhibitors) after coupling to URID giving active ester intermediates.  
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The most active mimetic in vitro, tunicamycin (AJ8) is a well known, non-specific natural product inhibitor 
of glycosyl transferase. Tunicamycin inhibits the transfer of Glc-NAc-1-P from UDP-GlcNAc to 
polyprenyl monophosphates in a variety of organisms including Gram positive bacteria. Phenothiazines 
(AJ4 and AJ5) gave moderate inhibition as expected from the reported MIC values of N-substituted 
phenothiazines (1-5 µg/mL). Phenothiazines have been reported to be inhibitors of type II 
NADH:menaquinone oxidoreductases (Weinstein et al, 2005). It is known that N-substituted phenothiazine 
possess unacceptable CNS side effects at high dose. Derivatives with improved activity would particularly 
be interesting to study their influence on mycothiol biosynthesis.   
Figure 2.10: Extracellular drug testing at 1 x 10
7 
M. tuberculosis per BACTEC 460™ vial containing 4 mL 
Middlebrook 7H12 medium. For control, M. tuberculosis was inoculated into BACTEC 460™ vials with 
no inhibitor or drug added.  
 
2.2.6 Antimicrobial activities of phenothiazines, tunicamycin, busulfan and nikkomycin 
Phenothiazines have been reported as inhibitors of type II NADH:menaquinone oxidoreductases (Martins 
et al, 2008). It is known that N-substituted phenothiazine possess unacceptable side effects on the central 
nervous system at high dose. Phenothiazines are known to exert significant mycobactericidal activity 
against M. tuberculosis strains resistant to first and second line antitubercular drugs (Weinstein et al, 2005). 
Derivatives of phenothiazines were tested for binding and inhibitory activity towards mshA. From the 
extracellular screening shown in figure 2.10, it was found that phenothiazines (AJ-4 and AJ-5) and 
tunicamycin (AJ-8) were effective for in vitro inhibition of M. tuberculosis. These findings were in 
agreement with the observations by Weinstein et al, 2005. Phenothiazines have been shown to exhibit high 
activity as anti-tubercular compounds, especially against M. tuberculosis strains that have resistance 
towards INH, RIF, streptomycin, PZA, and EMB combined.  
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The limitation of phenothiazines was that the concentration required in vitro for bacteriocidal activity was 
much greater than the clinical concentration of drug in vivo. It was against this background that substrate 
analogues of phenothiazines with greater activity were sought through derivatisation of parent compounds. 
Although phenothiazines are attractive in the treatment of M. tuberculosis, the fact that they are 
concentrated within the macrophages means that the dose required for treatment would be greatly reduced 
(Martins et al, 2008).  
 
It is reasonable to speculate that the modulation of electron transport in M. tuberculosis by phenothiazines 
may have a profound effect on the entrance and maintenance of dormancy. These compounds interfere with 
drug efflux pumps and mechanisms that inhibit the activation of Ca
2+-
dependent ATPase which generates 
H
+
 ions required for providing energy for activity of the pumps via the H
+
-ion gradient (Weinstein et al, 
2005). Phenothiazines may accelerate the course of TB treatment by interfering with bacterial persistence, 
thus making other anti-TB agents more effective. Although antimicrobial activities of phenothiazines have 
been well documented, their use against psychosis has led to complications in patients (Martins et al, 
2008). Among the compounds tested was busulfan (AJ-6), an anti-cancer drug given in vivo or in vitro to 
decrease hepatocyte glutathione by 60 and 50%, respectively (Martins et al, 2008). It was hypothesised that 
busulfan becomes conjugated to glutathione with and without the assistance of glutathione–S-transferase 
(Jardine, personal communication). The rationale for testing busulfan was therefore to understand how it 
interacts with the M. tuberculosis homolog, mycothiol.  
 
Nikkomycins (AJ-7) are peptidenucleoside antibiotics which competitively inhibit synthatase enzymes due 
to their close similarity to UDP-N-acetylglucosamine. These compounds have been reported to be non-
toxic and degrade easily, and could therefore be exploited as anti-mycobacterial agents in combination 
therapy (Decker et al, 1991). Despite these attractive features of nikkomycins, they have been found to be 
required in high concentrations for whole cell assay inhibition.  
 
 
- 32 - 
 
2.2.7 Thiozolidinone libraries (1A-12A and 1B-12B) 
Thiozolidinone libraries (1A-12A and 1B-12B) had moderate activity and were tested in enzyme assay, and 
were tested on in vitro growing M. tuberculosis (results shown in figure 2.11). Molecular dynamic docking 
experiments were performed in the mshA enzyme active site to aid further compound design. The 5‟-deoxy 
5-amino uridine and thiazolidinone 3-acetic acid amide coupling reaction provided a relatively unstable set 
of active ester intermediates (TA1-TA12) that displayed the highest potency (results shown in figure 2.13). 
 
 
 
Figure 2.11: Extracellular drug testing at 1 x 10
7 
M. tuberculosis per BACTEC 460™ vial containing 4 mL 
Middlebrook 7H12 medium. The relative BACTEC 460
TM
 values were used as a measure of M. 
tuberculosis growth index in Middlebrook medium.  
 
The promising compounds (1B, 2B, 7B, 12B and AJ-8) with highest inhibitory activity were used at three 
different concentrations (10, 1 and 0.1 µg/mL) and inhibition was monitored over time. The MICs of these 
compounds were established to be between 1 an 10 µg/mL (figure 2.7). However these compounds lost 
biological activity at concetrations below 1 µg/mL.  
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 Figure 2.13: Extracellular drug testing at 1 x 10
7 
M. tuberculosis per BACTEC 460™ vial containing 4 mL 
Middlebrook 7H12 medium. The relative BACTEC 460
TM
 values were used as a measure of M. tuberculosis 
growth index in Middlebrook medium.  
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Figure 2.12: Extracellular drug testing at 1 x 10
7
 CFUs
 
M. tuberculosis per BACTEC 460™ vial containing 4 mL 
7H12 Middlebrook medium.  
 
 
 
 
Inhibitor concentration (10 µg/mL) 
- 34 - 
 
 
 
 
Figure 2.14: Extracellular drug testing at 1 x 10
7 
M. tuberculosis per BACTEC 460™ vial containing 4 mL 
Middlebrook 7H12 medium. 
 
 
Figure 2.15: Extracellular drug testing at 1 x 10
7 
M. tuberculosis per BACTEC 460™ vial containing 4 mL 
Middlebrook 7H12 medium. 
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The mycobacteriocidal activities of the three sets of libraries (T1A-T12A, T1B-T12B and T1C-T12C) were 
done extracellularly on in vitro grown M. tuberculosis. Mycobacterial survival and death were monitored 
using the BACTEC 460
TM
 assay (see results in figure 2.13, figure 2.14 and figure 2.15). The T1A-T12A 
series of compounds showed increased activity relative to the T1B – T12B and T1C – T12C series. 
Increased inhibition of the T1A – T12A series was due to the non-selective nature in the reactivity of these 
compounds with any molecule containing amide moieties (Jardine, personal communication).  The T1C – 
T12C library was derivatised from T1B – T12B library through longer reaction times. However, from this 
library, only T1C gave highest inhibition of 50% at 10 µg/mL. Consequently, no further tests were done in 
the macrophage assay with this library of compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 36 - 
 
CHAPTER 3: INTRACELLULAR DRUG TESTING  
3.0 INTRODUCTION 
The aim of this study was to analyse the inhibitory activities of candidate inhibitors designed against 
enzymes of the mycothiol pathway, specifically mshA (a glycosyltransferase), by comparing the fate of M. 
tuberculosis in treated and untreated macrophages. In Chapter 2 a wide variety of drugs that affect enzymes 
of the mycothiol pathway were tested for their ability to prevent in vitro growth of M. tuberculosis. The 
most potent drugs in the in vitro studies were now used to test their ability to inhibit growth of M. 
tuberculosis within host macrophages. BACTEC 460
TM
 measurements were used to analyse bacterial 
survival within the macrophages. After extracellular screening of the most active compounds, intracellular 
testing was performed on THP1 cell line. Human macrophage-like cell line THP1 (ATCC TIB-202) was 
chosen for drug screening because these cells were much easier to obtain and culture. 
 
3.1 MATERIALS AND METHODS 
3.1.1 Culture conditions for the THP1 cell line 
The THP-1 human macrophage cell line were grown
 
at 37°C in 5% CO2 in RPMI 1640 (Sigma, USA) 
supplemented with 10%
 
heat-inactivated FCS (Gibco
TM
, Invitrogen, Germany) with penicillin-
streptomycin, 1% final concentration (Invitrogen). Cells were placed in a 50 ml tube + 8 ml (+/- 10 ml) 
medium and pelleted by spinning at 1 300  rpm for 5 minutes at 21
o
C. The supernatant was removed and 
the tube was dragged over round-bottom 96 well plate to re-suspend the pellet. A 10 ml aliquot of complete 
RPMI medium was added to the tube to re-suspend cells. All of the liquid was aliquoted into a flask (small 
filter cap TC flask), and incubated at 37
o
C for three days. Cells were checked everyday and fresh medium 
added every 2
nd
 or 3
rd
 day. Cells were harvested at 1 week, pelleted and re-suspend in fresh complete 
RPMI, lacking antibiotics and counted using a haemocytometer.   
 
THP-1 cells were differentiated into macrophages by using phorbol
 
myristic acetate (PMA, Sigma, USA). 
Once differentiated THP1 cells become adherent monolayers and stop dividing and to acquire typical 
characteristics of macrophages such as the capacity to phagocytize bacteria and to express bactericidal 
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activities (Tsuchiya et al, 1982). PMA was added to a final concentration of 100 nM and 1 mL of cells 
added per well in 24 well plates at a concentration of 5 x 10
5
 cells/mL (all experiments were done in 
triplicate). Cells were incubated overnight, and non-adherent cells were removed by washing 3 times with 1 
ml ice-cold phosphate buffered saline. At selected time points after infection with M. tuberculosis, infected 
macrophages were exposed to inhibitors of the mycothiol pathway, and intracellular survival was assessed. 
 
3.1.2 Macrophage infection 
1 mL aliquots of M. tuberculosis were removed from the -80
o
C freezer and thawed. Mycobacteria were 
passaged 30 times through a with 1 ml insulin syringe to remove clumps. The required amount of 
mycobacteria was centrifuged at 13 000 rpm for 20 minutes. The supernatant was removed and bacilli were 
re-suspended in 1 mL medium (RPMI, 10% FCS). The required amount was centrifuged at 13 000 rpm for 
20 minutes, and the supernatant removed. A 1 mL aliquot of medium (RPMI, 10% FBS) was added and 
passaged 10 times through a 1 ml insulin syringe. Macrophages were infected at an MOI of 5:1 and 
incubated for 4 hours at 37
o
C, in a 5% CO2 incubator. Non-ingested M. tuberculosis was then washed off 
with RPMI containing 10% FCS. Infected macrophages were incubated at 37
o
C in fresh medium that was 
renewed every 2 days thereafter.  
3.1.3 Evaluating inhibitory effects of novel compounds designed against the mycothiol pathway  
At day 1 or day 2 post infection, M. tuberculosis-infected macrophages were treated with candidate 
inhibitors of mycothiol enzymes to determine the optimal concentrations and treatment time for inhibitory 
effect on mycobacterial growth. At selected time-points during the drug treatments, infected macrophages 
were lysed with 0.1% Triton X-100 (Sigma-Aldrich, USA) to isolate M. tuberculosis. Mycobacteria were 
pelleted at 13 000 rpm for 20 minutes, and re-suspended in 1 ml 7H12 Middlebrook medium. The samples 
were analysed for M. tuberculosis growth in a BACTEC 460
™
 instrument. Inhibitory effects of each test 
compound were evaluated in relation to infected treated controls.  
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3.2 RESULTS AND DISCUSSION FOR INTRACELLULAR DRUG TESTING  
3.2.1 Drug testing in the macrophage assay 
THP-1 macrophages were infected with M. tuberculosis at an MOI 5:1 for up to 2 days. On day 3 post-
infection, M. tuberculosis-infected macrophages were treated with inhibitors of the mycothiol pathway, and 
incubated for different time-points (typically, 4, 8, 12 and 24 hrs) post-drug exposure.  
 
Inhibitor concentration (10 µg/mL) 
 
Figure 3.1: Intracellular drug testing on THP1 cells infected with M. tuberculosis at MOI 5:1. M. 
tuberculosis was inoculated into BACTEC 460™ vial containing Middlebrook 7H12 medium. In this 
figure, AJ-3 = substrate mimic for mycothiol enzymes, AJ-4 = phenothiazine, AJ-7 = nikkomycin, AJ-8 = 
tunicamycin. INH was used as a positive control at 0.05µg/mL concentration, while the negative control M. 
tuberculosis-infected macrophages without any drug added. 
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Figure 3.2: Intracellular drug testing on THP1 cells infected with M. tuberculosis at MOI 5:1. M. 
tuberculosis was 
 inoculated into BACTEC 460™ vials containing 4 mL Middlebrook 7H12 medium. 
 
As shown in figure 3.1, tunicamycin (AJ-8) was found to exhibit 95% inhibition on intracellular M. 
tuberculosis. In subsequent experiments, AJ-8 was used in order to determine its MIC in the macrophage 
environment. From the T1A-T12A series of compounds, none of these was found to display significant 
inhibition in the macrophage model, figure 3.2. Despite having shown good activity in the extracellular 
assay, figure 2.8, these compounds showed limited inhibition on the macrophage assay. The compound 
with highest potency in figure 3.2 was T2A which had 19% inhibition in the intracellular assay. We 
suggested that this library of inhibitors lost biological activity over time due to instability since they were 
reaction intermediates. The other two series of libraries (T1B-T12B and T1C-T12C) did not show any 
inhibition, suggesting that these compounds required structural modifications if they could be used in future 
studies.  
 
The CLICK and URID were tested for inhibition separately, figure 3.2 before coupling to the 1A-12A 
series of compounds so as to ascertain any contribution that these compounds would contribute towards 
biological activity of the T1A-T12A series. However URID and CLICK displayed very little difference 
when compared with the infected control (with no drug added), suggesting that the coupled groups would 
be responsible for biological activity in the macrophage system. Thus the activity observed in T1A and 
T2A was due, mainly to the substituent group.  
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CHAPTER 4: Assessment of morphological alterations of 
mycobacteria in macrophages after treatment with inhibitors 
of enzymes of the mycothiol pathway: and the resultant 
consequences on phagosome maturation 
 
4.1 INTRODUCTION  
Electron microscopy approaches were used to gain more insight into the fate of M. tuberculosis after 
treatment of infected macrophages with drugs designed against enzymes of the mycothiol pathway. The 
aims of this study were: (i) to determine if the inhibitors had any deleterious effects on the host 
macrophages, (ii) to characterise the ultra-structural modifications of mycobacteria, and (iii) to determine if 
the phagosome maturation block which is a major survival strategy of pathogenic mycobacteria was 
affected by inhibitors of the mycothiol pathway.  
 
It is well established that M. tuberculosis prevents phagosome maturation and therefore, fusion of 
phagosomes with lysosomes (reviewed e.g. in de Chastellier, 2008). This is considered to be a major 
survival strategy of pathogenic mycobacteria (de Chastellier et al, 1997; de Chastellier and Thilo, 2006, de 
Chastellier et al, 2009). Conclusive evidence by de Chastellier and Thilo (2006) shows that whenever 
phagosomes remain immature, the phagosome membrane is closely apposed all around to the 
mycobacterial surface. The authors proposed that whatever the molecular mechanisms involved in 
prevention of phagosome maturation, the establishment and maintenance of a close apposition around the 
mycobacterial surface is a requirement if phagosomes are to remain immature. This will occur when 
phagosomes contain a single bacterium (loner phagosomes).  
 
In contrast, when phagosomes contain several bacteria or clumps (social phagosomes), the phagosome 
membrane is no longer closely apposed to the bacterium in regions that span two adjacent bacteria. Such 
phagosomes systematically mature and fuse with lysosomes (Clements and Horwitz, 1995; de Chastellier 
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and Thilo, 1997). Immature and matured phagosomes cannot be distinguished directly under the electron 
microscope, and as a result, implicit parameters are used to determine whether phagosome maturation has 
occurred (de Chastellier and Thilo 1997). For this purpose, endocytic tracers such as HRP are added to cells 
before or after infection in order to locate and distinguish different compartments of the endocytic pathway.  
 
The study was initiated with THP-1 macrophages infected with M. tuberculosis. However THP-1 
macrophages often contained abnormal vesicles with dense material as well as autophagic vacuoles.  In 
addition, THP-1 cells were found to lift off the dishes and die within 2-4 days post-infection, depending on 
the MOI used. THP-1 cells could therefore not be used for experiments which required longer periods of 
drug exposure. Furthermore, THP-1 cells were found to have a small lysosomal compartment and we 
thought that this might jeopardise studies on fusion of M. tuberculosis containg phagosomes with 
lysosomes. Mouse BMDMs were therefore used in subsequent experiments as these have been successfully 
used in several laboratories studying phagosome processing (e.g. de Chastellier et al 1995).  
 
4.2 MATERIALS AND METHODS 
4.2.1 Bacterial strains and culture conditions 
M. tuberculosis and M. avium were used to study the effects of different inhibitors of the mycothiol 
pathway on intracellular survival. Mycobacterial culture conditions were similar to those described 
previously in Chapters 2 and 3.  
 
4.2.2 Culturing of mouse bone marrow derived macrophages (BMDM) 
Bone marrow cells were obtained from femurs of 6-8 week-old C57BL/6 female mice and seeded into 
tissue culture dishes of 35 mm diameter or in 6-well tissue culture plates. The culture medium was 
Dulbecco‟s Modified Eagles Medium (DMEM, Invitrogen, USA) with high glucose (1g/L) and high 
carbonate (3.7g/L) concentrations supplemented with 10% heat-inactivated FCS (Gibco, USA), 10% L-929 
cell conditioned medium (a source of colony stimulating factor-1), and 1% glutamine (Sigma, USA). At 5 
days after seeding, adherent cells were washed twice with DMEM and re-fed with complete medium. 
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Medium was then renewed on day 6 and no antibiotics were added at any one point during the culturing 
process.  
 
4.2.3 Infection of macrophages with mycobacteria and treatment with selected drugs 
BMDMs were infected with M. avium or M. tuberculosis. Inhibitors of enzymes of the mycothiol pathway 
were added to infected macrophages at selected time points post-infection and different concentrations. 
Infected macrophages without treatment were used as experimental controls. At selected time points of 
treatment, cells were fixed and processed for transmission electron microscopy via a collaborative study 
with Dr. Chantal de Chastellier at the Centre d'Immunologie de Marseille-Luminy, France. 
 
4.2.4 HRP uptake and staining for HRP  
At selected time-points during drug treatment, infected cells were incubated for 1hr at 37
o
C in complete 
medium containing 25 µg/mL or 1 mg/mL HRP. HRP was stained with an enzyme cytochemistry method 
(de Chastellier et al, 1995; de Chastellier, 2009). Cells were fixed with 2.5% glutaraldehyde in 0.1M 
cacodylate buffer, pH 7.2, containing 0.1M sucrose, 5mM CaCl2 and 5mM MgCl2 for 1 hr at room 
temperature. After 2 washes for 15 minutes with cacodylate buffer with sucrose. 
 
4.2.5 Processing of samples for transmission electron microscopy 
Cells were fixed for 1 hour at room temperature with OsO4, 1% in cacodylate buffer devoid of sucrose. 
After 3 brief washes with sodium cacodylate buffer devoid of sucrose cells were scraped off the tissue 
culture dishes with a rubber policeman and then concentrated in 2% agar prepared in 0.1 M cacodylate 
buffer devoid of sucrose. Samples were dehydrated with a graded series of ethanol (25%, 50%, 75%, 90% 
each for 15 min, and 100% ethanol dried on molecular sieves, 3times for 30 min). Samples were embedded 
in Spurr resin. For this purpose ethanol was progressively replaced by Spurr resin by incubating samples in 
increasingly higher concentrations of Spurr (Spurr: ethanol ratios of 1:3, 1:1, 3:1) for 1 hour each at room 
temperature.  Samples were immersed in pure Spurr resin at room temperature for 3 hours at room 
temperature, followed by 3 hours at 37
o
C. Samples were then placed in moulds to which Spurr resin was 
added and incubated at 60
o
C for polymerisation of resin. Blocks of embedded cells were sectioned and 
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observed using a Zeiss EM912 transmission electron microscope. Embedded cells were randomly sectioned 
in all directions to ensure a correct representation and phagosome count. 100–200 phagosomes per sample 
were examined. 
  
4.3 RESULTS AND DISCUSSION  
Macrophages were infected with M. avium and M. tuberculosis and then treated with two drugs designed 
against enzymes of the mycothiol pathway, i.e. tunicamycin (AJ-8) and phenothiazine (AJ-4). These drugs 
were chosen for treatment of infected macrophages because they seemed to be potent inhibitors of M. 
tuberculosis growth in the extracellular and intracellular assays (reported in Chapters 2 and 3).  
 
4.3.1 Morphological appearance of infected macrophages treated with selected inhibitors  
4.3.1.1 Treatment with tunicamycin (AJ-8) 
 Macrophages infected with M. tuberculosis or M. avium were treated with tunicamycin (AJ-8) at different 
concentrations and time points.  Ultra-structural changes in M. tuberculosis or M. avium-infected and drug 
treated macrophages were compared to the control experiments, figure 4.1. Infected cells were incubated 
with HRP at either 25 µg/mL or 1 mg/mL to locate lysosomal compartments which appear as dark and 
dense vacuoles within the cytoplasm.  After treatment with tunicamycin (AJ-8) at 5µg/mL for 24 hours, the 
endoplasmic reticulum of cells was found to be swollen, but ribosomes were still attached. The cytoplasm 
was less dense than usual due to extraction of protein or cell components from the cytoplasm, thereby 
indicating that cells were undergoing permeabilisation and cell lysis. Cholesterol crystals were observed to 
be accumulating in lysosomes. Cisternae of Golgi apparatus were swollen, suggesting that the observed 
effects were due to tunicamycin. With lower concentrations of tunicamycin, cells were less frequently lysed 
but they still displayed the above alterations and a large proportion were permeabilised. Tunicamycin being 
cytotoxic to macrophages, was abandoned as a potential drug candidate.  
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Figure 4.1: Electron micrographs showing macrophages infected with M. tuberculosis and then exposed to 
inhibitors of enzymes of the mycothiol pathway: (A) = control macrophages infected with M. tuberculosis, 
(B) = macrophages infected with M. tuberculosis and exposed to AJ-8, and (C) = macrophages infected 
with M. tuberculosis and exposed to AJ-4. In these electron micrographs, Ly = lysosome, GA = Golgi 
apparatus, Ph = phagosome, IB = intact bacteria, N = nucleus, LC = lysed cell, PC = permeabilised cell, IC 
= intact cell.  
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Ph 
(A) (B) 
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4.3.1.2 Treatment with phenothiazine (AJ-4) 
Cells treated with different concentrations of phenothiazine, i.e. 25 µg/mL, 10 µg/mL and 1 µg/mL. At 
higher concentrations, phenothiazine resulted in cell lysis, i.e. 100% and >80% cell lysis at 25 µg/mL and 
10 µg/mL, respectively. At 1 µg/mL phenothiazine, cells were found to be morphologically intact, and this 
concentration was used for further drug testing and morphological assessments. These observations 
indicated that phenothiazine could be used as an inhibitor since it had no deleterious effects on the 
macrophages. Subsequent experiments were done with phenothiazine to investigate its killing effects on M. 
tuberculosis within infected macrophages.  
 
4.3.2 Ultra-structural appearance of M. tuberculosis within infected macrophages treated with 
phenothiazine (AJ-4) 
 
Mouse BMDMs were infected with M. tuberculosis, MOI 2:1, treated with phenothiazine (AJ-4) at 1 
µg/mL starting from day 4 post-infection and fixed at day 5 post-infection after 1 day and at day 7 after a 3-
day treatment. We then determined the effect of drug treatment in terms of its morphological alterations on 
M. tuberculosis, figure 4.2. Intracellular bacteria were sorted into two distinct categories on the basis of 
their morphological appearance (Fréhel et al, 1997): (i) intact bacteria which display a regular shape, a well 
organized nuclear region and cytoplasm with few or no intracellular lipid inclusions, and an intact 
cytoplasmic membrane and cell wall  with  an electron translucent outer wall layer; and (ii) degraded 
bacteria which characteristically display breaks in the cell wall and/or cytoplasmic membrane, a 
disorganized cytoplasm.  
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(A)                                                                              (B) 
Figure 4.2: Assessment of morphological alterations of M. tuberculosis in macrophages treated with AJ-4. 
In this figure, (A) is the control showing intact bacteria and normal morphology for both cells and M. 
tuberculosis, (B) is AJ-4 treated macrophages infected with M. tuberculosis. IB= intact bacteria, DB = 
damaged bacteria, M = mitochondrion, ER = endoplasmic reticulum. The zone of exclusion was used as an 
indicator of damaged bacteria. 
 
After a 1 day treatment, the bacilli had the same morphological appearance as bacteria residing within 
untreated macrophages, i.e. were morphologically intact as defined above. After a 3-day treatment, part of 
the bacilli displayed morphological alterations. The most obvious alteration was evidenced by exclusion of 
cytoplasm and DNA from the centre of the bacilli, suggesting that bacilli were undergoing degradation and 
therefore being killed. We then determined the percentage of bacilli that were intact in drug treated 
macrophages (Table 4.1). After 1 day treatment, the percentage of intact bacilli was similar to that observed 
for untreated cells, i.e. 86% vs 91%. In contrast, after 3-days of treatment only 55% of the bacilli were 
intact. These results suggested that phenothiazine was a potent inhibitor of mycothiol biosynthesis in M. 
tuberculosis. 
 
IB 
DB 
Ph 
ER M 
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Table 4.1: Percentages of intact bacilli: in this table mouse BMDM were infected with M. tuberculosis at 
MOI 2:1. At day 4 post-infection, AJ-4 was added at 1 µg/mL for 24 hours or 72 hours. Control 
experiments were mouse BMDM + M. tuberculosis without AJ-4.  
 
AJ-4 conc Time of treatment Time of fixation % intact bacteria (average %) 
 
- - D5 p.i 91.3% 
 
- 
 
- D7 p.i 
 
85.8% 
 
1 µg/mL 
 
24 hr D5 p.i 85.6% 
 
1 µg/mL 
 
72 hr 
 
D5 p.i 54.6% 
 
 
 
4.3.3 Phagosome processing after treatment of infected macrophages with phenothiazine (AJ-4) 
BMDM were infected with M. tuberculosis at MOI 2:1 with 1 µg/mL AJ-4 for 3 days. As recalled in the 
Introduction of Chapter 4, only phagosomes containing a single live mycobacterium (loner phagosome), 
can remain immature whereas those containing several bacilli systematically mature and fuse with 
lysosomes. If for some reason bacilli are unable to block loner phagosome maturation, the later are 
processed into phagolysosomes that can fuse together to form phagolysosomes containing several bacilli. 
We therefore determined whether the percentage of social phagosomes and of bacteria enclosed in social 
phagosomes increased in the presence of AJ-4. We found no differences between the control and drug-
treated cells since the percentage of social phagosomes was 40 % of the total in drug-treated vs 31 % in the 
control case. In both cases 70% of the bacteria were enclosed in social phagosomes. 
 
In the second set of experiments, BMDM were infected with M. tuberculosis at an MOI of 2:1. Five days 
later cells were treated with 1 µg/mL AJ-4 for 3 days. Before processing for TEM, cells were first 
incubated for 1 hour with HRP at a concentration of 25 µg/mL. After fixation with glutaraldehyde HRP 
was stained by cytochemical methods as described in the Materials and Methods section. The use of HRP 
serves two purposes. First, it allows to distinguish early endosomes from lysosomes which differ in their 
cytochemical staining pattern, figure 4.3. Secondly, it allows to discriminate between immature 
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phagosomes that fuse with early endosomes and matured phagosomes that no longer fuse with early 
endosomes but fuse with lysosomes to become phago-lysosomes.  
 
The morphological appearance of loner phagosomes that do not contain HRP is shown in  figures 4.3 (A) 
and 4.4 (A), of loner phagosomes that fuse with lysosomes and therefore become HRP positive is shown in 
figure 4.4 (B). Social phagosomes showing HRP reaction product are shown in figure 4.3 (B). and figure 
4.4 (B).  
 
(A)      (B) 
Figure 4.3: Fate of loner and social phagosomes on the maturation block. (A) Mouse BMDMs were 
cultured for 6 days, and infected with M. tuberculosis at an MOI of 2:1. No inhibitor (AJ-4) was added, and 
fixation was done on day 7 after HRP uptake for 1 hour. E = early endosome, and L = lysosomes, both 
showing a positive stain for HRP. In the electron micrograph, a single phagosome (with 2 bacteria) can be 
seen with a rim of HRP (arrow).  All bacteria appear morphologically intact. (B) Mouse BMDMs cultured 
for 6 days, and infected with M. tuberculosis at an MOI 2:1. At day 4 post-infection, inhibitor AJ-4 was 
added at 1µg/mL for 72 hours, after which cells were fixed at day 7 after HRP uptake for 1 hour. The arrow 
shows HRP staining in a phagosome containing several bacteria. This phagosome contains 5 intact bacteria 
and perhaps 1 damaged bacterium, indicated as D. The phagosome with a single bacterium (1B) did not 
stain positive with HRP.  
D 
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(A)     (B) 
Figure 4.4: Loner and social phagosomes are processed differently during the endocytic pathway. (A) In 
this electron micrograph, both the phagosome containing a single bacterium (1B) and the one with 2 
bacteria (2B) stain positive for HRP as indicated by the arrows. All bacteria are morphologically intact. (B) 
The arrow shows a phagosome containing a single bacterium with positive HRP staining, and a damaged 
(D) bacterium (no cytoplasm), L = lysosome.  
 
 
The percentages of HRP positive loner and social phagosomes are shown in Tables 4.2 and 4.3. Drug 
treatment did not result in an increase in the percentage of HRP positive loner phagosomes.  
 
Table 4.2: Proportion of loner phagosomes (1B) that were HRP-positive 
 
AJ-4 conc Time of treatment Time of fixation % HRP
+
 
- 
 
- 
 
D7 p.i 
 
 
52 % 
30.1% (correct literature value) 
1 µg/mL 
 
72 hr 
 
D7 p.i 
 
59% 
 
We observed that about 90% of the social phagosomes had fused with lysosmes in agreement with data 
from de Chastellier et al, 2005.  
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Table 4.3: Proportion of social phagosomes (≥2B) that were HRP-positive 
 
AJ-4 conc Time of treatment Time of fixation % HRP
+ 
 
- 
 
- 
 
D7 p.i 
 
87 % 
1 µg/mL 
 
72 hr 
 
D7 p.i 
 
85% 
 
These studies provide evidence that phenothiazine can induce morphological alterations in bacteria, 
however we did not observe major differences in phagosome processing in the presence of the drug. 
Further studies would therefore be required if this drug can be fully exploited as an inhibitor of the 
mycothiol pathway in M. tuberculosis.  
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CHAPTER 5: GENERAL RECOMMENDATIONS 
FOR FUTURE DIRECTIONS 
5.1 TB Research Opportunities 
This study attempted to address critical areas that require additional research and new product development 
in order to close the TB knowledge gap. Specifically, mycothiol was studied as a potential drug target by 
testing inhibitors designed against enzymes involved in its biosynthesis. The identification of novel drug 
targets continues to be used as an important tool in drug discovery. In this way, various genes have been 
knocked out in M. tuberculosis with the idea of establishing essentiality of genes and result phenotype.  
 
Russell et al (2010) suggested that instead of investigating on gene knock-outs alone during drug 
discovery, it was necessary to integrate the interaction between gene products and metabolic pathways 
which are required for survival in the hostile internal environment of the macrophages. In this work, M. 
tuberculosis infected-macrophages were screened to establish the responses when macrophages were 
exposed to conditions to stress such as drugs.  
 
5.2 Structural biology/biology (e.g. elucidations of TB/host interactions)  
Genes involved in mycothiol biosynthesis have been deleted using conventional gene knock-out strategies 
except for the mshC that we attempted to knock-out using the conditional knock-out strategy. Novel MSH 
binding proteins; macrophage interactions have been implicated in resistance mechanisms in M. 
tuberculosis; but the question remains as to how TB bacilli remain in macrophages for such long periods of 
time. It would also be ideal to investigate how bacilli keep macrophages from or “activating”. Persistent 
bacteria have been a major problem in TB treatment; hence it would be interesting to investigate what 
accounts for these persistent TB populations? Is it lack of drug penetrations in all cell types, or 
mutant/tolerant bacilli? For efficient clearances of bacilli from the granulomas, it would be desirable to 
have drugs that have increased killing rates and sterilisations. 
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5.3 Target validations/drug efficacy (e.g. validations through chemical inhibition)  
In order to increase the screening process for hit compounds it would be desirable to develop medicinal 
chemistry protocols and high throughput screening systems that also involve whole cell screening. A wide 
range of validated binding pockets have been modelled and computationally screened by the group of Dr 
Anwar Jardine at the University of Cape Town.  
 
Attempts have also been made (by medicinal chemists) to investigate the range of protein/ligand co-
crystallisations as well as measuring/monitoring in real-time the drug penetrations in vitro, in vivo and 
within macrophages. Electron microscopy was used to follow the fate of M. tuberculosis within 
macrophages, but more biochemical techniques were required to establish the physiochemical properties 
necessary for drugs to penetrate dormant TB bacilli. In particular, what drug properties are required to 
penetrate the waxy coat of bacilli and their protective granulomas? 
 
5.4 Therapeutics (e.g. efficacious, expeditious, and inexpensive drugs or diagnostics)  
In this study of mycothiol as a drug target the Phase I milestone was to demonstrate feasibility, enzyme-to-
whole cell inhibition, phase II milestone would be to provide lead compound screens and optimisations. 
Different compounds were tested for in vitro inhibition of M. tuberculosis, and different macrophage 
systems were used as models to study how mycobacteria are processed within the cell.  
 
5.5 Diagnostics (e.g. to monitor and differentiate TB strains, point of care diagnostics).  
In order to address issues of TB transmission, it would be desirable if diagnostic tools to identify active and 
latent TB infections could be developed.  In view of this objective it would be worthwhile to identify which 
host and pathogen biomarkers are indicative of disease progression or cessation. Are sequestered persistent 
persistent-bacilli detectable? Can sensitive and reliable diagnostics devices be made inexpensively? Can 
TB be imaged? Can spectroscopic analytical techniques help monitor disease progression? Can small 
numbers of “active” TB bacilli be detected in the host? Can TB physiology and clearance be monitored? 
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APPENDIX I 
CULTURING OF L-929 FIBROBLASTS (SOURCE OF CSF-1 FOR BMD MOUSE 
MACROPHAGES) 
I Medium  
Complete medium is RPMI 1640 or DMEM + 10% FCS (heat inactivated) + 2mM L-glutamine.  
Trypsin 0.05%/ EDTA 0.02% (TE) to trypsinise the cells  
 
II Cell culturing  
(Start from a new frozen stock aliquot each time. You may want to prepare    L-cell conditioned medium) 
 
a) Step 1:  
Put 1mL medium in the first 6 wells of a 24 well tissue culture plate (Falcon). Thaw (rapidly) 1 cryotube of 
L-cells (stored in liquid nitrogen - contains 1 mL at approx 1-2 x 10
6
 cells/mL). Put the contents of the 
cryotube in the first well, then do 5 successive two-fold dilutions in the next 5 wells. Do not wash and/or 
centrifuge cells before. Let them grow for 24-48 hrs at 37
o
C in 5-7.5% CO2. After 24 hrs add 1 mL fresh 
medium 
 
b) Step 2: 
48 hrs later cells have started to grow. They are still spindle-shaped and have not yet reached full 
confluence. Trypsinise cells of the last 3 wells as follows: 
Put 1 mL trypsin-EDTA, remove immediately (this allows to remove excess FCS). 
Put 250 mL TE/well. Incubate for 2-3 minutes at 37
o
C. 
Collect cells of the 3 wells into a centrifuge tube (containing 10 mL of complete medium (to stop reaction, 
cool on ice). Centrifuge at 1200 rpm for 3 minutes, at 4
o
C. Do not count cells at this stage. 
 
 
 
- 61 - 
 
c) Step 3: 
Re-suspend pellet first in 1 mL, then add and additional 5 mL of complete medium 
Put the 5 mL in a 25 cm
2
 tissue culture flask (Falcon is the best) 
Let cells grow for two days at 37
o
C in 7.5% (or 5%) CO2 incubator 
 
d) Step 4: 
Cells should be close to confluence (spindle shaped, not cubic) 
Trypnize cells as follows: 
Put 1 mL T-EDTA, remove  immediately 
Put 2 mL T-EDTA, incubate cells at 37
o
C for 2-3 minutes  
Collect cells and put into centrifuge tube containing 10 mL of ice cold complete medium 
Count cells before spinning them down 
Centrifuge at 1200 rpm, 3 minutes at 4
o
C 
 
e) Step 5 
Dilute cells, in order to have 5 x 10
4
cells/mL, in complete medium 
Put 10 mL per 25 cm
2
 tissue culture dish. We prepare 3 flasks to have enough cells for final expansion 
Let cells grow for 2-3 days 
Trypsinise as before 
 
Step 6: Production of L-cell conditioned medium 
Dilute cells in order to have 2.5 x 10
4
cells/mL 
Distribute in 75cm
2
 tissue culture flasks (Falcon), 40 mL/flask. We prepare 6 to 8 flasks in order to be able 
to work with the same batch of L-cell conditioned medium for a while. Let the cells grow. This time they 
must reach confluence, become tightly packed and even reach the point where they are about to (but 
haven't) come off the flask. This is when they produce the most CSF-1. At D + 6 collect supernatant, filter 
on 0.22 µm filter, aliquot and store at -20
o
C. This is the L-cell conditioned medium. It can be kept for 
several months. One can freeze and thaw it 2 or 3 times but it would be advisable not to do it more often 
(so sizes of aliquots depend on how much you need each time you prepare medium). 
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APPENDIX II 
RELEVANT WORK ASSOCIATED WITH MSC TRAINING 2009-2010 
A. CONFERENCES 
1. Anwar Jardine, Bienyameen Baker, James Mazorodze, Dirk Lapmrecht. (2009). Overcoming the 
crisis of TB and AIDS. Keystone Symposium, Arusha, Tanzania.  
2. James Mazorodze, Anwar Jardine, Chantal Chastellier, Paul van Helden and Bienyameen Baker. 
(2010).
 
Importance of mycothiol as a defense molecule in Mycobacterium tuberculosis. Capebiotech 
Forum Conference, Somerset West, Capetown.  
B. TRAINING  
1. MSc training in advanced tissue culture, cell biology and electron microscopy (under the mentorship of 
Dr Chantal de Chastellier) at the Centre d’Immunologie de Marseille-Luminy (CIML), Aix-Marseille 
Universite´, Faculte´ des Sciences de Luminy, Marseille, France under the French-South Africa 
Bilateral Agreement, 1
st
 – 31st October 2009 and 8th October – 3rd November 2010. 
2. Trained under the Stanford-South Africa Biomedical Informatics Program‟s short course in Genomics: 
Micro-arrays and High throughput Sequencing, 10-14
th
 May 2010 held at the University of the 
Western Cape in South Africa.  
3. Trained and successfully completed the Collaborative Institutional Training Initiative (awarded the 
CITI: Human Research Curriculum Completion Certificate) under Fogarty Global Infectious Diseases 
Fellowship. 2010. 
4. MS Excel Postgraduate training course, sponsored by the Postgraduate International Office, 
Stellenbosch University, 2009. 
C. AWARDS AND SCHOLARSHIPS 
1. Awarded a 3 months Fellowship (July – September 2010) under the Fogarty International Scheme: 
Short-Term Pre-doctoral Traineeship in TB Research at the Howard Hughes Medical Institute (Dr 
William Jacobs Jr Laboratory), Albert Einstein College of Medicine (Yeshiva University) USA.  
2. Recipient of University Bursary for MSc Medical Biochemistry studies for the period 2009/2010 
(Stellenbosch University). 
